Do analysts recommend AYTU or SNOA?

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 383.15%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NRSN or SNOA?

NeuroSense Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 1,082.20%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TXMD or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer NCEL or SNOA?

NLS Pharmaceutics presently has a consensus price target of $23.00, suggesting a potential upside of 500.52%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, NCEL or SNOA?

Sonoma Pharmaceuticals has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Sonoma Pharmaceuticals $19.53M 0.30 -$3.17M -$1.89 N/A

Do analysts rate ZIVO or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sonoma Pharmaceuticals (SNOA) Competitors

$1.21 -0.02 (-1.87%)

As of 01:28 PM Eastern

Compare

SNOA vs. AYTU, NRSN, TXMD, NCEL, and ZIVO

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? MarketBeat compares Sonoma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sonoma Pharmaceuticals include Aytu BioPharma (AYTU), NeuroSense Therapeutics (NRSN), TherapeuticsMD (TXMD), NLS Pharmaceutics (NCEL), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.87 beat Sonoma Pharmaceuticals' score of 0.30 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
Sonoma Pharmaceuticals	Neutral

Sonoma Pharmaceuticals has a net margin of -16.26% compared to Aytu BioPharma's net margin of -60.17%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 383.15%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sonoma Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$56.60M	0.42	-$13.56M	-$4.58	N/A
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.89	N/A

Aytu BioPharma has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

Aytu BioPharma beats Sonoma Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Sonoma Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.89	N/A

NeuroSense Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. NeuroSense Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

NeuroSense Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 1,082.20%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroSense Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 2 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.13 beat Sonoma Pharmaceuticals' score of 0.30 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Positive
Sonoma Pharmaceuticals	Neutral

Summary

NeuroSense Therapeutics beats Sonoma Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat Sonoma Pharmaceuticals' score of 0.30 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Sonoma Pharmaceuticals	Neutral

TherapeuticsMD has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.35M	6.77	-$570K	$0.06	32.67
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.89	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TherapeuticsMD has a net margin of 5.34% compared to Sonoma Pharmaceuticals' net margin of -16.26%. TherapeuticsMD's return on equity of 0.32% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Sonoma Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

NLS Pharmaceutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.89	N/A

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NLS Pharmaceutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. NLS Pharmaceutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

NLS Pharmaceutics presently has a consensus price target of $23.00, suggesting a potential upside of 500.52%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NLS Pharmaceutics had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 3 mentions for NLS Pharmaceutics and 2 mentions for Sonoma Pharmaceuticals. NLS Pharmaceutics' average media sentiment score of 0.72 beat Sonoma Pharmaceuticals' score of 0.30 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Sonoma Pharmaceuticals	Neutral

Summary

NLS Pharmaceutics beats Sonoma Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 0 mentions for ZIVO Bioscience. Sonoma Pharmaceuticals' average media sentiment score of 0.30 beat ZIVO Bioscience's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Sonoma Pharmaceuticals	Neutral

Sonoma Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.89	N/A

ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

ZIVO Bioscience has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. ZIVO Bioscience's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 2.3% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Sonoma Pharmaceuticals beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.92M	$2.99B	$6.79B	$12.62B
Dividend Yield	N/A	2.08%	2.68%	8.43%
P/E Ratio	-0.65	18.84	27.04	24.39
Price / Sales	0.30	352.48	521.74	91.34
Price / Cash	N/A	56.83	48.59	59.39
Price / Book	1.89	4.24	10.83	6.31
Net Income	-$3.17M	$65.13M	$3.59B	$331.45M
7 Day Performance	-0.73%	-2.66%	-1.30%	0.26%
1 Month Performance	10.90%	2.02%	2.97%	-0.64%
1 Year Performance	-66.55%	23.26%	28.58%	20.24%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	0.2196 of 5 stars	$1.21 -1.9%	N/A	-66.6%	$5.78M	$19.53M	N/A	180
AYTU Aytu BioPharma	2.7472 of 5 stars	$2.18 -3.1%	$10.75 +393.1%	+2.3%	$23.40M	$56.60M	N/A	160	Gap Down
NRSN NeuroSense Therapeutics	3.5298 of 5 stars	$0.71 +0.1%	$8.50 +1,099.5%	-63.5%	$23.07M	N/A	N/A	10	Gap Down
TXMD TherapeuticsMD	1.3164 of 5 stars	$1.97 flat	N/A	+68.4%	$22.80M	$3.35M	32.83	420
NCEL NLS Pharmaceutics	3.6167 of 5 stars	$4.23 +5.5%	N/A	-81.3%	$22.63M	N/A	N/A	6	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. AYTU, NRSN, TXMD, NCEL, and ZIVO

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Sonoma Pharmaceuticals compare to NeuroSense Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Sonoma Pharmaceuticals compare to NLS Pharmaceutics?

Summary

How does Sonoma Pharmaceuticals compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. AYTU, NRSN, TXMD, NCEL, and ZIVO

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Does the media refer more to AYTU or SNOA?

Is AYTU or SNOA more profitable?

Do analysts recommend AYTU or SNOA?

Do insiders and institutionals believe in AYTU or SNOA?

Which has stronger valuation and earnings, AYTU or SNOA?

Which has more volatility & risk, AYTU or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to NeuroSense Therapeutics?

Which has better valuation & earnings, NRSN or SNOA?

Is NRSN or SNOA more profitable?

Do analysts recommend NRSN or SNOA?

Which has more risk & volatility, NRSN or SNOA?

Do insiders and institutionals believe in NRSN or SNOA?

Does the media favor NRSN or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

Does the media refer more to TXMD or SNOA?

Which has preferable earnings & valuation, TXMD or SNOA?

Do insiders & institutionals have more ownership in TXMD or SNOA?

Is TXMD or SNOA more profitable?

Which has more risk and volatility, TXMD or SNOA?

Do analysts prefer TXMD or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to NLS Pharmaceutics?

Which has more risk & volatility, NCEL or SNOA?

Which has stronger valuation & earnings, NCEL or SNOA?

Do insiders and institutionals have more ownership in NCEL or SNOA?

Is NCEL or SNOA more profitable?

Do analysts prefer NCEL or SNOA?

Does the media refer more to NCEL or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to ZIVO Bioscience?

Do analysts rate ZIVO or SNOA?

Does the media favor ZIVO or SNOA?

Which has stronger earnings & valuation, ZIVO or SNOA?

Which has more volatility and risk, ZIVO or SNOA?

Is ZIVO or SNOA more profitable?

Do institutionals & insiders have more ownership in ZIVO or SNOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools